- Home
- AMZE vs PHIO Comparison
AMZE vs PHIO Comparison
Compare AMZE & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMZE
- PHIO
- Stock Information
- Founded
- AMZE 2019
- PHIO 2011
- Country
- AMZE United States
- PHIO United States
- Employees
- AMZE N/A
- PHIO 5
- Industry
- AMZE Beverages (Production/Distribution)
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- AMZE Consumer Staples
- PHIO Health Care
- Exchange
- AMZE Nasdaq
- PHIO Nasdaq
- Market Cap
- AMZE 8.0M
- PHIO 8.6M
- IPO Year
- AMZE 2021
- PHIO N/A
- Fundamental
- Price
- AMZE $0.43
- PHIO $1.78
- Analyst Decision
- AMZE
- PHIO Strong Buy
- Analyst Count
- AMZE 0
- PHIO 1
- Target Price
- AMZE N/A
- PHIO $4.00
- AVG Volume (30 Days)
- AMZE 78.9K
- PHIO 1.1M
- Earning Date
- AMZE 05-27-2025
- PHIO 05-27-2025
- Dividend Yield
- AMZE N/A
- PHIO N/A
- EPS Growth
- AMZE N/A
- PHIO N/A
- EPS
- AMZE N/A
- PHIO N/A
- Revenue
- AMZE $299,065.00
- PHIO N/A
- Revenue This Year
- AMZE N/A
- PHIO N/A
- Revenue Next Year
- AMZE N/A
- PHIO N/A
- P/E Ratio
- AMZE N/A
- PHIO N/A
- Revenue Growth
- AMZE N/A
- PHIO N/A
- 52 Week Low
- AMZE $0.34
- PHIO $0.97
- 52 Week High
- AMZE $0.62
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- AMZE N/A
- PHIO 47.26
- Support Level
- AMZE N/A
- PHIO $1.70
- Resistance Level
- AMZE N/A
- PHIO $2.09
- Average True Range (ATR)
- AMZE 0.00
- PHIO 0.17
- MACD
- AMZE 0.00
- PHIO -0.04
- Stochastic Oscillator
- AMZE 0.00
- PHIO 20.00
About AMZE Amaze Holdings Inc. Common Stock
Amaze Holdings Inc provides a platform with a suite of solutions for easy product design and creation, commerce design applications, social commerce integrations, and services that enable creators to unlock their full creative and financial potential.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.